AZD1775

DRUG19 trials

Sponsors

AstraZeneca, National Cancer Institute (NCI), St. Joseph's Hospital and Medical Center, Phoenix, Samsung Medical Center, H. Lee Moffitt Cancer Center and Research Institute

Conditions

Advanced Gastric AdenocarcinomaAdvanced Solid TumoursCancerCarcinoma, Squamous Cell of Head and NeckGBMGlioblastomaHypopharynx Squamous Cell CarcinomaLarynx Cancer

Early Phase 1

A Phase 0 Study of AZD1775 in Recurrent GBM Patients

CompletedNCT02207010

St. Joseph's Hospital and Medical Center, PhoenixGBM, Glioblastoma

Start: 2014-07-31End: 2019-03-25Updated: 2020-12-10

Phase 1

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

CompletedNCT02194829

National Cancer Institute (NCI)Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7 +1

Start: 2014-08-19End: 2022-12-21Updated: 2023-04-25

Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours

CompletedNCT02341456

AstraZenecaAdvanced Solid Tumours

Start: 2015-01-16End: 2018-07-09Updated: 2019-03-25

AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors

CompletedNCT02511795

AstraZenecaRefractory Solid Tumours, Relapsed Small Cell Lung Cancer (SCLC)

Start: 2015-08-06End: 2019-10-16Updated: 2019-11-07

Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer

Active, not recruitingNCT02546661

AstraZenecaMuscle Invasive Bladder Cancer

Start: 2016-12-28End: 2026-01-30Updated: 2025-12-29

Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC

CompletedNCT02585973

UNC Lineberger Comprehensive Cancer CenterCarcinoma, Squamous Cell of Head and Neck

Start: 2015-10-26End: 2021-06-23Updated: 2021-06-29

Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.

CompletedNCT02610075

AstraZenecaLocally Advanced Solid Tumours, Metastatic Solid Tumours, Ovarian Cancer

Start: 2015-12-01End: 2018-04-26Updated: 2023-07-03

Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours

CompletedNCT02617277

AstraZenecaAdvanced Solid Tumours

Start: 2015-12-28End: 2026-02-17Updated: 2026-03-04

Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer

CompletedNCT02906059

NYU Langone HealthMetastatic Colorectal Cancer

Start: 2016-09-30End: 2020-03-12Updated: 2020-10-12

WEE1 Inhibitor with Cisplatin and Radiotherapy: a Trial in Head and Neck Cancer

CompletedNCT03028766

University of BirminghamHypopharynx Squamous Cell Carcinoma, Larynx Cancer, Oral Cavity Squamous Cell Carcinoma

Start: 2017-06-22End: 2021-02-03Updated: 2024-09-19

Phase 2

A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer

TerminatedNCT02087176

AstraZenecaPreviously Treated Non Small Cell Lung Cancer

Start: 2014-03-31End: 2015-05-31Updated: 2016-06-14

Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer

TerminatedNCT02087241

AstraZenecaPreviously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer

Start: 2014-03-31End: 2015-06-30Updated: 2017-03-29

Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy

CompletedNCT02448329

Samsung Medical CenterAdvanced Gastric Adenocarcinoma

Start: 2015-01-14End: 2021-04-19Updated: 2022-06-15

AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer

CompletedNCT02513563

H. Lee Moffitt Cancer Center and Research InstituteLung Cancer

Start: 2015-10-13End: 2023-11-28Updated: 2026-02-19

OLAParib COmbinations

TerminatedNCT02576444

Joseph Paul EderCancer

Start: 2015-11-30End: 2019-11-18Updated: 2022-12-28

Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients

CompletedNCT02593019

Samsung Medical CenterSmall Cell Lung Cancer

Start: 2015-12-31End: 2018-10-31Updated: 2021-03-19

Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients With MYC Family Amplification or CDKN2A Mutation Combined With TP53 Mutation

TerminatedNCT02688907

Samsung Medical CenterSmall Cell Lung Cancer

Start: 2016-06-07End: 2018-09-12Updated: 2018-09-20

CISPLATIN + AZD-1775 In Breast Cancer

CompletedNCT03012477

Dana-Farber Cancer InstituteTriple-negative Metastatic Breast Cancer

Start: 2017-01-18End: 2020-11-30Updated: 2021-11-23

AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma

Active, not recruitingNCT03668340

Dana-Farber Cancer InstituteUterine Cancer

Start: 2018-10-22End: 2027-07-01Updated: 2026-01-12

Related Papers

Two Phase II Trials of Adavosertib, a Wee1 Inhibitor with Docetaxel or Carboplatin plus Pemetrexed in Non-small-cell Lung Cancer.

2025-11-10

Open-Label, Multicenter, Phase I Study to Assess Safety and Tolerability of Adavosertib Plus Durvalumab in Patients with Advanced Solid Tumors

Targeted Oncology2024-11-196 citations

Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial

Targeted Oncology2024-11-015 citations

A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i> <i>-</i> Altered Advanced Solid Tumor Malignancies (NCI 10170)

Cancer Research Communications2024-06-2611 citations

A phase II trial of AZD1775 plus carboplatin-paclitaxel in squamous cell lung cancer (SqCLC).

Journal of Clinical Oncology2024-06-011 citations

Results and lessons learnt from the WISTERIA phase I trial combining AZD1775 with cisplatin pre- or post-operatively in head and neck cancer

BJC Reports2024-01-294 citations

A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors.

2023-06-0625 citations

Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS).

2021-05-2445 citations

An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer.

2021-05-0384 citations

PLANETTE: A modular phase IIa multicenter open-label study evaluating the ATR inhibitor ceralasertib (AZD6738) in ATM mutant advanced solid tumors.

Journal of Clinical Oncology2021-02-203 citations

A phase II trial of the Wee1 inhibitor adavosertib (AZD1775) in recurrent uterine serous carcinoma.

Journal of Clinical Oncology2020-05-2011 citations

Phase I trial of WEE1 inhibition with chemotherapy and radiotherapy as adjuvant treatment, and a window of opportunity trial with cisplatin in patients with head and neck cancer: the <b>WISTERIA</b> trial protocol

BMJ Open2020-03-0137 citations

Safety, Pharmacokinetics, and Clinical Activity of Adavosertib in Combination with Chemotherapy in Asian Patients with Advanced Solid Tumors: Phase Ib Study.

2020-02-0117 citations

Abstract A080: Olaparib and the ATR inhibitor AZD6738 in relapsed, refractory cancer patients with homologous recombination (HR) repair mutations – OLAPCO

Molecular Cancer Therapeutics2019-12-018 citations

Abstract CT025: Phase Ib study of adavosertib in combination with olaparib in patients with refractory solid tumors: Dose escalation

Cancer Research2019-07-0125 citations

Abstract CT022: A Phase Ib study of Wee1 inhibitor adavosertib in patients with advanced solid tumors

Cancer Research2019-07-017 citations

Abstract CT025: Phase Ib study of adavosertib in combination with olaparib in patients with refractory solid tumors: Dose escalation

Clinical Trials2019-07-013 citations

Abstract CT022: A Phase Ib study of Wee1 inhibitor adavosertib in patients with advanced solid tumors

Clinical Trials2019-07-01

Open-label, multicenter, phase I study to assess safety and tolerability of adavosertib plus durvalumab in patients with advanced solid tumors.

Journal of Clinical Oncology2019-05-2029 citations

Biomarker driven phase II umbrella trial study of AZD1775, AZD2014, AZD2811 monotherapy in relapsed small cell lung cancer.

Journal of Clinical Oncology2019-05-2012 citations

9 more papers not shown